Mark H Rozenbaum

Summary

Affiliation: University of Groningen
Country: The Netherlands

Publications

  1. ncbi Cost-effectiveness of varicella vaccination programs: an update of the literature
    Mark H Rozenbaum
    Groningen Research Institute of Pharmacy GRIP, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Expert Rev Vaccines 7:753-82. 2008
  2. ncbi Dynamic models for health economic assessments of pertussis vaccines: what goes around comes around
    Mark H Rozenbaum
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Expert Rev Vaccines 11:1415-28. 2012
  3. ncbi The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis
    M H Rozenbaum
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands
    Eur J Clin Microbiol Infect Dis 32:305-16. 2013
  4. ncbi Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis
    Mark H Rozenbaum
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, Netherlands
    BMJ 345:e6879. 2012
  5. ncbi Cost-effectiveness of pertussis booster vaccination in the Netherlands
    Mark H Rozenbaum
    Unit of PharmacoEpidemiology and PharmacoEconomics PE 2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Vaccine 30:7327-31. 2012
  6. ncbi Modelling the impact of extended vaccination strategies on the epidemiology of pertussis
    M H Rozenbaum
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, The Netherlands
    Epidemiol Infect 140:1503-14. 2012
  7. ncbi Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model
    Mark H Rozenbaum
    Unit of PharmacoEpidemiology and PharmacoEconomics PE2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    BMC Public Health 11:462. 2011
  8. ncbi Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination
    Mark H Rozenbaum
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Expert Rev Vaccines 10:187-99. 2011
  9. ncbi Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar)
    Mark H Rozenbaum
    Unit of PharmacoEpidemiology and PharmacoEconomics PE 2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Vaccine 28:2367-9. 2010
  10. ncbi Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines
    Mark H Rozenbaum
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, Netherlands
    BMJ 340:c2509. 2010

Detail Information

Publications17

  1. ncbi Cost-effectiveness of varicella vaccination programs: an update of the literature
    Mark H Rozenbaum
    Groningen Research Institute of Pharmacy GRIP, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Expert Rev Vaccines 7:753-82. 2008
    ..Despite that, those aspects limit the timeliness of our review and we believe that the current work does provide useful insights in the cost-effectiveness of varicella vaccination...
  2. ncbi Dynamic models for health economic assessments of pertussis vaccines: what goes around comes around
    Mark H Rozenbaum
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Expert Rev Vaccines 11:1415-28. 2012
    ..In future, dynamic transmission models for pertussis should be used widely to further enhance understanding of pertussis epidemiology and of extended pertussis vaccination programs that are currently considered in various countries...
  3. ncbi The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis
    M H Rozenbaum
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands
    Eur J Clin Microbiol Infect Dis 32:305-16. 2013
    ..This study provides estimates of the average observed prevalence of S. pneumoniae, which could be used for projecting the health and economic benefits of pneumococcal immunization...
  4. ncbi Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis
    Mark H Rozenbaum
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, Netherlands
    BMJ 345:e6879. 2012
    ..To estimate the cost effectiveness of vaccinating people with high risk conditions against invasive pneumococcal disease using the 13 valent pneumococcal conjugate vaccine...
  5. ncbi Cost-effectiveness of pertussis booster vaccination in the Netherlands
    Mark H Rozenbaum
    Unit of PharmacoEpidemiology and PharmacoEconomics PE 2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Vaccine 30:7327-31. 2012
    ..To conclude, we show that extended pertussis booster vaccination strategies are likely to be considered as cost-effective...
  6. ncbi Modelling the impact of extended vaccination strategies on the epidemiology of pertussis
    M H Rozenbaum
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, The Netherlands
    Epidemiol Infect 140:1503-14. 2012
    ..The impact of the different assumptions used in the model was in general limited. We conclude that over a wide range of assumptions, an additional booster dose can reduce the incidence of pertussis in the population...
  7. ncbi Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model
    Mark H Rozenbaum
    Unit of PharmacoEpidemiology and PharmacoEconomics PE2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    BMC Public Health 11:462. 2011
    ..We aimed to investigate which factors had a major impact on cost-effectiveness and were primarily responsible for the large differences in previously estimated cost-effectiveness ratios...
  8. ncbi Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination
    Mark H Rozenbaum
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Expert Rev Vaccines 10:187-99. 2011
    ..We conclude that the health and economic impact should be addressed in light of the country specific pneumoccocal disease epidemiology to support decisions on immunization programs...
  9. ncbi Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar)
    Mark H Rozenbaum
    Unit of PharmacoEpidemiology and PharmacoEconomics PE 2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Vaccine 28:2367-9. 2010
    ....
  10. ncbi Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines
    Mark H Rozenbaum
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, Netherlands
    BMJ 340:c2509. 2010
    ....
  11. ncbi Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands
    Mark H Rozenbaum
    Department of Pharmacy, University of Groningen, The Netherlands
    Clin Ther 32:1517-32. 2010
    ..Community-acquired pneumonia and invasive pneumococcal disease are common among older people (ie, those aged > or =65 years). A new 13-valent pneumococcal conjugate vaccine (PCV-13) is under study in the Netherlands...
  12. ncbi Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries
    Hong Anh T Tu
    Unit of PharmacoEpidemiology and PharmacoEconomics PE 2, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Vaccine 30:1521-8. 2012
    ....
  13. ncbi On discounting of health gains from human papillomavirus vaccination: effects of different approaches
    Tjalke A Westra
    Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    Value Health 15:562-7. 2012
    ..Different approaches to discount health effects have been proposed. In this study, we estimated the impact of different approaches for discounting health benefits of human papillomavirus (HPV) vaccination...
  14. ncbi A review of the literature on the economics of vaccination against TB
    Hong Anh T Tu
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Expert Rev Vaccines 11:303-17. 2012
    ....
  15. ncbi Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world
    Maarten J Postma
    Unit of PharmacoEpidemiology and PharmacoEconomics PE2, Department of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands
    BMC Med 9:84. 2011
    ....
  16. ncbi Economic evaluations of rotavirus immunization for developing countries: a review of the literature
    Hong Anh T Tu
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Expert Rev Vaccines 10:1037-51. 2011
    ....
  17. ncbi Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations
    Stefan Vegter
    Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
    Clin Ther 32:1651-61. 2010
    ....